1. Context
2. Evidence Acquisition
3. Results
3.1. Vitamin A
3.1.1. Introduction
3.1.2. The Role of Vitamin A in Infections
3.1.3. Vitamin A and UTI
| Variables | ||||
|---|---|---|---|---|
| Author | Dalirani et al. (7) | Ayazi et al. (19) | Sobouti et al. (21) | Kahbazi et al. (22) |
| Method | Single-blinded randomized clinical trial | Single-blinded randomized clinical trial | Simple non-blind, open-label randomized clinical trial | Randomized, double-blind, placebo-controlled clinical trial |
| Year | 2011 | 2011 | 2013 | 2018 |
| Country | Tehran, Iran | Qazvin, Iran | Tehran, Iran | Arak, Iran |
| Number of participants (case/control) | 76 (37/39) | 50 (25/25) | 40 (20/20) | 74 (36/38) |
| Antibiotic treatment | Intravenous ceftriaxone 75 mg/kg for 10 days | Intravenous ceftriaxone 75 mg/kg twice a day for 10 days, followed by oral cephalexin (15 mg/kg) | According to the antibiogram profile, cephalothin or ampicillin (100 mg/kg/day 4 times daily) and amikacin (15 mg/kg/day 3times daily) for 10 days | Intravenous ceftriaxone 75 mg/kg/d followed by oral cephalexin (15 mg/kg) for 10 days. |
| Vitamin A treatment b | ||||
| Duration | First 3 days of admission | During admission | 10 days | 10 days |
| Route | Intramuscular | Intramuscular | Oral | Oral |
| Placebo | None | None | None | Once daily for 10 days |
| Follow-up time, mo | 6 | 3 | 6 | 6 |
a All the studies used a technetium-99m DSMA (dimercaptosuccinic acid) scan for renal scarring assessment.
b All the studies administered vitamin A at 1 500 U/kg/d with a maximum dose of 50 000 units.
3.2. Vitamin C
3.2.1. Introduction
3.2.2. The Role of Vitamin C in Infections
3.2.3. Vitamin C and UTI
3.3. Vitamin D
3.3.1. Introduction
3.3.2. The Role of Vitamin D in Infections
3.3.3. Vitamin D and UTI
3.4. Vitamin E
3.4.1. Introduction
3.4.2. Vitamin E and Kidney Disease
| Variables | |||
|---|---|---|---|
| Author | Sobouti et al. (21) | Yousefichaijan et al. (66) | Ghasemi et al. (65) |
| Method | A simple, non-blind, open-label, randomized clinical trial | A double-blinded randomized controlled trial | A single-blinded randomized controlled trial |
| Year | 2013 | 2015 | 2022 |
| Country | Tehran, Iran | Arak, Iran | Bandar Abbas, Iran |
| Number of participants (case/control) | 40 (20/20) | 152 (76/76) | 78 (37/41) |
| Age range, mo | 1 – 120 | 60 – 144 | 3 - 168 |
| Antibiotic treatment | According to the antibiogram profile, cephalothin or ampicillin (100 mg/kg/day 4 times daily) and amikacin (15 mg/kg/day 3times daily) for 10 days | Intravenous ceftriaxone 50 - 75 mg/kg/d, twice daily during hospitalization, and 8 mg/kg/d of oral cefixime twice daily after discharge | Intravenous ceftriaxone 50 - 75 mg/kg/d during the hospital stay |
| Vitamin E treatment duration b | 10 days | 14 days | 4 months |
| Placebo | None | Once daily | None |
| Follow-up time, mo | 6 | 4 – 6 | 4 |
a All the studies used a technetium-99m DSMA (dimercaptosuccinic acid) scan for renal scarring assessment.
b All the studies administered vitamin E as 20 U/kg/d by the oral route and capsules of 100 IY.


